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Background: 2-Methoxyestradiol is known to have antitumour and antiproliferative action in vitro and in vivo.
However, when 2-methoxyestradiol is orally administered, it is rapidly oxidized by the enzyme 17β-hydroxysteriod
dehydrogenase in the gastrointestinal tract. Therefore, 2-methoxyestradiol never reaches high enough concentrations
in the tissue to be able to exert these antitumour properties. This resulted in the in silico-design of 2-methoxyestradiol
analogues in collaboration with the Bioinformatics and Computational Biology Unit (UP) and subsequent synthesis by
iThemba Pharmaceuticals (Pty) Ltd (Modderfontein, Midrand, South Africa). One such a novelty-designed analogue is
2-ethyl-3-O-sulphamoyl-estra-1, 3, 5(10)16-tetraene (ESE-16).
Methods: This pilot study aimed to determine the morphological effect and possible generation of reactive
oxygen species by ESE-16 on erythrocytes and platelet samples (with and without added thrombin) by means
of scanning electron microscopy, transmission electron microscopy and flow cytometry.
Results: Erythrocytes and platelets were exposed to ESE-16 at a concentration of 180nM for 24 hours. Scanning- and
transmission electron microscopy indicated that ESE-16 did not cause changes to erythrocytes, platelets or fibrin networks.
Flow cytometry measurements of hydrogen peroxide and superoxide indicated that ESE-16 does not cause an increase in
the generation of reactive oxygen species in these blood samples.
Conclusion: Further in vivo research is warranted to determine whether this novel in silico-designed analogue may impact
on development of future chemotherapeutic agents and whether it could be considered as an antitumour agent.
Keywords: 2-Methoxyestradiol analogues, 2-Ethyl-3-O-sulphamoyl-estra-1, 3, 5(10)16-tetraene, Reactive oxygen species,
CancerIntroduction
Cancer is currently one of the leading causes of mortality
across the world’s population [1]. Research aimed at find-
ing possible compounds to treat or cure cancer is there-
fore of extreme importance. 2-Methoxyestradiol (2ME)
(Figure 1) is a metabolite of 17β-estradiol which has been
tested for its antitumour and antiangiogenic properties
in vitro and in vivo [2,3].
2ME however, has poor bioavailability limiting the ac-
tion in vivo as indicated in earlier phase I studies where* Correspondence: annie.joubert@up.ac.za
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unless otherwise stated.2ME was orally administered to cancer patients in the
form of a capsule [5]. The rate at which 2ME becomes
available to the site of drug action is low since the rate
of oxidation of 2ME is higher than absorption [5]. 2ME
is rapidly oxidized in the gastrointestinal tract when or-
ally administered by the enzyme 17β-hydroxysteriod de-
hydrogenase [6,7]. This leads to decreased levels of
2ME, thus being too low to exert significant antitumour
effects [8]. The development of a 2ME NanoCrystal® col-
loidal dispersion (NCD) was subsequently formulated.
The latter increased bioavailability, however, the antitu-
mour effects were not optimal in patients [9]. This led
to the development and synthesis of analogues of 2MEl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 Structure of 2-methoxyestradiol [4].
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antiangiogenic properties with increased bioavailability
[10,11]. Such analogues of 2ME have been in silico-
designed in our laboratory (Figure 2). One novel in silico-
designed analogue is 2-ethyl-3-O-sulphamoyl-estra-1, 3, 5
(10)16-tetraene (ESE-16) (Figure 2).
2ME exerts its anticancer signaling by disrupting mito-
chondrial function, generating reactive oxygen species
(ROS) and by targeting microtubule dynamics in vitro
and in vivo [13]. 2ME results in apoptosis involving both
the extrinsic and intrinsic pathways [14]. 2ME activates
apoptosis via the extrinsic pathway by means of deathFigure 2 Synthesis of various sulphamoylated analogues of 2-methox
of the sulphamoylated compound ESE-16 are indicated in the image in stereceptors (DRs) such as death receptor 5 (DR5) and acti-
vates caspases known to promote the extrinsic pathway
[14]. The extrinsic pathway of apoptosis comprises of
the instigation of caspase 8, caspase 3, and upregulation
of DR5 with activation of caspase 9 present in the intrin-
sic pathway through crosstalk with caspase 8 [14,15].
Production of ROS in 2ME- and analogue-treated cells
is likely to be a result of the inhibition of the mitochon-
drial electron transport complex I [13] leading to autoph-
agy by means of beclin-1 upregulation and autophagy
protein 4 (Atg4) inactivation [16]. Generation of ROS
upregulates beclin-1 which results in the increased inci-
dence of autophagy, while hydrogen peroxide causes au-
tophagy and the inactivation of Atg4 responsible for the
induction of autophagy [17]. 2ME also induces apoptosis
in cancer cells as a result of the upregulation of p53, since
p53 is known to arbitrate cell cycle arrest that may lead to
the induction of apoptosis by controlling the G2/M cell
cycle checkpoint [18,19].
Previous morphological studies of 2ME-treated cancer
cells have shown the presence of characteristics of
apoptosis including cell membrane blebbing, apoptotic
bodies, cell shrinkage and hypercondensation of chro-
matin [20]. The presence of altered chromosomes and
spindles has also been morphologically determined and
indicates the occurrence of micronuclei, atypicalyestradiol. Synthesis of 2-ethyl estrone derivatives and the structure
p 12 [12].
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multipolar spindles [18,21].
The mechanism of action of 2ME is via impairment of
microtubule dynamics by binding to the β-tubulin’s col-
chicine binding site and thereby inhibiting mitotic spin-
dle function, leading to blocking of cells in mitosis and
eventually cell death [22-25]. Of the various analogues of
2ME, 2-ethyl derivatives in silico-designed, were deter-
mined to have increased binding to the colchicine binding
site, thus leading to increased disruption of microtubule
dynamics in the cell and G2/M arrest [26-28].
Previously in our laboratory, it was determined that the
newly designed analogues are more potent when compared
to 2ME, disrupting α-tubulin dynamics resulting in apop-
tosis and autophagy. The effect of ESE-16 was previously
determined on a non-tumorigenic MCF-12A cell line in our
laboratory and it was demonstrated that ESE-16 had
decreased discernment towards the non-tumorigenic cell
line when compared to a cancer cell line [29]. These sul-
phamoylated analogues have increased anticancer activity
as they bind to carbonic anhydrase II (CAII) present in
red blood cells delaying early metabolism [12,29].
This preliminary study aimed to determine the influ-
ence of ESE-16 on erythrocytes and platelets in terms of
morphology and generation of reactive oxygen species
(ROS) by means of scanning electron microscopy, trans-
mission electron microscopy and flow cytometry. The
time and concentration at which erythrocytes and plate-
lets were exposed were previously established in our la-
boratory by means of growth inhibition studies (GI50)
[12]. The effect of ESE-16 on the structure of erythro-
cytes, platelets and fibrin networks has not yet been
determined and as this compound is theorized to be
carried in the blood bound to CAII, the effect of ESE-
16 on the morphology of erythrocytes, platelets and fi-
brin networks is significant [12]. This study reveals the
ex vivo potential of this compound as a study tech-
nique to establish the specific mechanisms of action
and future studies will determine the involvement of
all related systems. Data from this study merits further
in vivo research to determine the impact of this novel
in silico-designed analogue on development of future
chemotherapeutic agents and whether it could be con-




Images obtained from SEM analysis indicated the nor-
mal morphology of fibrin networks, platelets and eryth-
rocytes. ESE-16-treated samples showed no damage as
seen in positive control samples or deviation from the
normal morphology when compared to the control sam-
ples (Figure 3).Transmission electron microscopy
Illustrations of TEM analysis indicated that ESE-16-
treated platelets (Figure 4C and D) were not affected
with similar morphology to platelets in control samples
(Figure 4A and B) including granularity and membrane
integrity. Whole blood control samples (Figure 4A and
B) indicated normal morphology of erythrocytes. Whole
blood samples exposed to ESE-16 (Figure 4C and D) re-
vealed normal erythrocyte morphology with no sign of
distress.
Reactive oxygen species generation
Hydrogen peroxide measurement
To examine the generation of hydrogen peroxide after
exposure of blood samples to ESE-16 when compared to
control- and vehicle-treated samples, flow cytometry was
used in combination with the DCFDA probe. Hydrogen
peroxide generation was not increased when blood
samples were treated with ESE-16 compared to the
control samples (Figure 5A) and was validated with
the use of Cyflogic version 1.2.1 software (Pertu Therho,
Turko, Finland).
Superoxide measurement
Superoxide generated from ESE-16-treated blood sam-
ples was determined by means of flow cytometry using
the HE probe. Superoxide generation was revealed not
to be statistically significantly increased in ESE-16 treated
cells (indicated in green graphs) when compared to con-
trol samples (indicated in red graphs) (Cyflogic version
1.2.1 software (Pertu Therho, Turko, Finland) (Figure 5B).
Discussion
The GI50 concentration and exposure time of 2-ethyl-3-
O-sulphamoyl-estra-1, 3, 5(10)16-tetraene (ESE-16) have
previously been established in our laboratory [12]. The
current study is the first to report on the ex vivo effects
potentiated by ESE-16. Previous studies suggest that
ESE-16′s mechanism of action induce both apoptosis
and autophagy in the tumorigenic cell lines attributed to
the formation of reactive oxygen species.
Apoptosis can be induced by ROS production gener-
ated from Fas ligand which binds to Fas receptors and
recruits Fas-associating protein with death domain. Cas-
pase 8 culminates in apoptosis and characteristically
DNA fragmentation as one of the hallmarks of this type
of cell death [30]. ROS generation may also induce au-
tophagy by means of Beclin-1 upregulation, inactivation
of autophagy protein 4 (Atg4) and increased expression of
autophagy protein 5 (Atg5) which result in self-catabolism
of cellular organelles and degradation in lysosomes [30].
The latter accounts for the increased formation of acidic
vacuoles characterized by autophagy [16,17,30]. Genes in-
volved in the activation of apoptosis and autophagy caused
Figure 3 Scanning electron microscopy images of control and ESE-16-treated fibrin networks, platelets and erythrocytes. The addition
of thrombin to PRP resulted in the formation of fibrin networks (A - scale indicates 1 μm). Fibrin networks formed from ESE-16-treated PRP
samples indicated normal fibrin morphology (B - scale indicates 1 μm). Control plasma smears to show platelet morphology (without thrombin)
indicated normal morphology of platelets (C - scale indicates 1 μm) which corresponded with the morphology of ESE-16-treated platelets (D - scale
indicates 2 μm) and is not similar to positive control DMSO-treated platelets which clearly reveals platelet activation (E - scale indicates
2 μm). Whole blood samples (prepared from whole blood smears without thrombin) indicated biconcave morphology of control erythrocytes
(F - scale indicates 1 μm) which resembled the morphology seen in ESE-16-treated erythrocytes (G - scale indicates 1 μm) but not that of
DMSO-treated erythrocytes at a concentration of 1% as positive control showing signs of oxidative stress with membrane lengthening (H - scale
indicates 1 μm).
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Figure 4 Transmission electron microscopy images of control and ESE-16-treated platelets and erythrocytes. Plasma control samples
showed normal morphology of platelets including granularity (α- and dense granules) and presence of mitochondria (A – scale indicates 2 μm &
B – scale indicates 1 μm). Platelets exposed to ESE-16 indicated no effect on platelet morphology or interior cellular structures and granularity of
the platelets remained intact (C – scale indicates 2 μm & D – scale indicates 1 μm). Whole blood control samples indicated normal morphology
of erythrocytes (E & F - scale indicates 2 μm). Whole blood exposed to ESE-16 showed no significant damage or structural changes to the morphology
or membrane of erythrocytes (G & H - scale indicates 2 μm).
Repsold et al. Cancer Cell International 2014, 14:48 Page 5 of 8
http://www.cancerci.com/content/14/1/48when MCF-7 cells are treated with ESE-16 was deter-
mined with the use of gene and protein microarrays in
our laboratory [29]. These studies also revealed that MCF-
7-treated cells undergo apoptosis through activation of
the c-Jun NH(2)-terminal kinase (JNK) pathway induced
by ruptured lysosomes, increased labile iron, ROS produc-
tion and Bcl-2 phosphorylation [29].
Further data from in vitro studies in our laboratory
showed that ESE-16 induces apoptosis and generation of
ROS in cancer cell lines [12,29,31-33]. ESE-16 has also been
tested on the non-tumorigenic MCF-12A breast cells and
have shown a higher affinity for the cancerous cell lines
when compared to this non-cancerous cell line [31-33].
The current study shows that no morphological character-
istics of ROS generation were seen via SEM and TEM or
even quantitatively by means of flow cytometry.
Since ESE-16 was designed to ultimately serve as a
treatment for cancer, it was imperative to test the effect
ESE-16 might have on the morphology of platelets, fibrin
networks and erythrocytes when administered and dis-
tributed through the circulatory system. The ex vivo ef-
fects of ESE-16, however, showed no distress or damage
to platelets or fibrin networks implying that ESE-16 has
no effect on the activation of the coagulation cascade.
TEM analysis did not show any deviations from thenormal morphology of the erythrocytes. The formation
of reactive oxygen species in blood samples when ex-
posed to ESE-16 was not increased and treatment with
ESE-16 does thus not result in the generation of ROS in
blood samples. From the results it has been determined
that ESE-16 does not cause distress when administered
ex vivo to platelets, erythrocytes or fibrin networks thus
indicating the viability of ESE-16 to be applied to in vivo
studies.
Conclusion
In conclusion, ESE-16′s effects in vitro are favorable as a
promising antitumour agent causing metaphase block,
apoptosis and autophagy in tumorigenic cell lines and
not to the same extent in MCF-12A cells. In the current
study it was shown that no damage was caused to the
morphological structure of platelets, fibrin networks or
erythrocytes. Reactive oxygen species was not increased
when blood samples were exposed to ESE-16. Data dem-
onstrate the possibility of ESE-16 as a potential anticancer
candidate, causing no damage to circulatory components.
In the light of these preliminary data future ex vivo and
in vivo research is warranted to investigate whether this
novel in silico-designed analogue might be considered as
an antitumour agent.
Figure 5 Measurement of ROS production in control and ESE-16-treated blood samples. Hydrogen peroxide detection utilizing DCFDA
probe of control blood samples (A) and ESE-16-treated samples (B) showed no statistical difference. Superoxide detection utilizing HE probe
indicated control blood samples (C) and ESE-16-treated blood samples (D) which once again indicated not statistically significant (a P-value
of less than 0.05 was accepted as statistically significant).
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Blood
Blood for ex vivo analysis was obtained from 3 healthy
males who did not smoke or have not used any medica-
tion. Blood was collected in citrate tubes which were ac-
quired from Transpharm (Gauteng, SA). Platelet-rich
plasma (PRP) was obtained by centrifuging the blood
sample at 1000 rpm for 2 min and collecting plasma
from the separated blood [34]. Whole blood (200 μl) and
PRP (200 μl) were exposed to ESE-16 for 24 hours in
96-well plates [34]. To prepare fibrin clot or coagulum,
human thrombin (20 U/ml) containing 0.2% human
serum albumin (obtained from the South African Na-
tional Blood Service, Gauteng, South Africa) was added
to PRP samples and ESE-16-exposed PRP samples to de-
termine whether ESE-16 would have an effect on the
coagulation process of plasma [34]. Platelets were studied
by making PRP smears on glass cover slips, while erythrocyte
morphology were studied by making whole blood smears on
glass cover slips (here no thrombin was added).
2-Ethyl-3-O-sulphamoyl-estra-1, 3, 5(10)16-tetraene (ESE-16)
ESE-16 is an in silico-designed compound derived from
2ME in collaboration with the Bioinformatics and Com-
putational Biology Unit (UP) and is therefore not com-
mercially available. Synthesis was conducted by iThembaPharmaceuticals (Pty) Ltd (Modderfontein, Midrand, South
Africa). The concentration and time at which samples were
exposed to ESE-16 was previously determined in our labora-
tory via growth inhibition 50 (GI50) studies and was found
to be 180 ± 10.76 nM [12]. Ex vivo blood samples were
therefore exposed to 180 nM of ESE-16 for 24 hours for
SEM, TEM and ROS measurement [12].
Scanning electron microscopy
Ex vivo samples were prepared on glass plates as follows:
10 μl whole blood as a control, 10 μl whole blood with
5 μl thrombin, 10 μl whole blood exposed to ESE-16,
10 μl whole blood exposed to ESE-16 with 5 μl throm-
bin, 10 μl whole blood exposed to DMSO at a concen-
tration of 1% (v/v) as a positive control. PRP samples
composed of 10 μl PRP as a control, 10 μl PRP with 5 μl
thrombin, 10 μl PRP exposed to ESE-16, 10 μl PRP ex-
posed to ESE-16 with 5 μl thrombin, and 10 μl PRP ex-
posed to DMSO at a concentration of 1% (v/v) as a
positive control. Glass plates with ex vivo samples were
placed in 6-well plates and left to dry until a film
formed, after which the samples were washed for 20 min
in a 50% phosphate buffered saline (PBS): 50% distilled
H2O solution. Samples were fixed with gluteraldehyde
and PBS for 30 min and washed 3 times in PBS for
3 min each for subsequent secondary fixation in osmium
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each for 3 min and dehydrated for 3 min each in in-
creasing concentration of ethanol, 30%, 50%, 70%, 90%
and three times in 100% ethanol [34,35]. Samples were
critically dried, mounted and carbon coated and was
viewed with the Zeiss ULTRA plus FEG-SEM (Carl Zeiss
(Pty) Ltd, Johannesburg, South Africa).
Transmission electron microscopy
Whole blood and PRP were obtained and samples were
exposed to ESE-16 with appropriate controls included as
previously defined. Blood samples were fixed for 30 min
in the same solution and rinsed in 50% PBS: 50% dis-
tilled H2O solution (three times for 3–5 min each).
Blood samples were fixed with osmium tetraoxide solu-
tion for 15 min and washed three times with PBS: dis-
tilled H2O solution (1:1) for 3 min. Samples were
dehydrated by emerging in 30%, 50%, 70%, 90% and
three times in 100% ethanol, whereafter samples were
embedded in Quetol resin for 36 hours. Samples were
cut with an ultra microtome into ultra-thin sections with
a diamond knife and contrasted for 15 min with 4% ur-
anyl acetate and lead citrate for 10 min [36]. The JOEL
Transmission electron microscope (JEM 2100 F) situ-
ated at the Microscopy and Microanalysis Unit of the




Generation of hydrogen peroxide (H2O2) produced by
whole blood and PRP was assessed using 2,7-dichloro-
fluorescein diacetate (DCFDA). When DCFDA is oxi-
dized by ROS and peroxides in the samples it is converted
to a highly fluorescent derivative of the non-fluorescent
DCFDA, namely 2,7-dichlorofluorescein (DCF) [17,37].
After samples including previously-mentioned controls
were prepared and exposed as described, 10 μl whole
blood and 10 μl PRP in 1 ml PBS was used with 0.75 μl
DCFDA (10 mM) probe for 20 min at 37°C. Measurement
of DCF (FL1) fluorescence was conducted for at least 10
000 events (n value = 3) with a FC500 System Flow Cyt-
ometer (Beckman Coulter South Africa(Pty) Ltd.) which is
equipped with an 488 nm excited air-cooled argon laser.
Data analysis was conducted with the use of Cyflogic ver-
sion 1.2.1 software (Pertu Therho, Turko, Finland) [8].
Superoxide measurement
Generation of superoxide was measured in whole blood
and PRP samples exposed to ESE-16 along with appro-
priate controls with the use of hydroethidine (HE). HE is
only oxidized by superoxide to a red fluorescent com-
pound and not by any other form of ROS including
hydrogen peroxide, singlet oxygen, nitrogen radicals orhydroxyl radicals [17,37]. After whole blood and PRP
were exposed, 10 μl whole blood and 10 μl PRP were re-
suspended in 1 ml PBS and incubated with 0.75 μl HE
probe (20 mM) for 20 min at 37°C. Red fluorescence
produced by samples was measured as the HE fluores-
cent product (FL2) for at least 10 000 events (n value = 3)
with a FC500 System Flow Cytometer (Beckman Coulter
South Africa(Pty) Ltd.) which is equipped with an 488 nm
excited air-cooled argon laser. Data analysis was obtained
with the use of Cyflogic version 1.2.1 software (Pertu
Therho, Turko, Finland) [8].
Statistics
Number of subjects included for this pilot study was
corroborated by the Department of Statistics at the
University of Pretoria. In addition, and separate from
the number of subjects included, quantitative and qualita-
tive techniques were conducted in triplicate. Qualitative
data capturing included SEM and TEM images and were
confirmed by quantitative data. Quantitative data included
measurement of ROS by HE- and DCF- derived fluores-
cence which was expressed as a ratio of the value measured
for the ESE-16-treated cells compared to the vehicle-treated
exposed cells defined as mean relative fluorescence. This in-
volved flow cytometry analysis of at least 10 000 events that
was repeated thrice and statistical significance was deter-
mined by employing Cyflogic version 1.2.1 software (Pertu
Therho, Turko, Finland).
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